kasks83 Posted - 16 hours ago

$EOLS what happen? :(

Stock_Titan Posted - 1 day ago

$EOLS Evolus to Report First Quarter Financial Results on May 7, 2024 https://www.stocktitan.net/news/EOLS/evolus-to-report-first-quarter-financial-results-on-may-7-tqvci23bf2oh.html

SpacePanda Posted - 1 day ago

$EOLS anyone know whats going on with the shareholder lawsuit? Going on 4 years now must be close to a settlement right?

Doorkey Posted - 4 days ago

$EOLS Long swing. waiting, 9$ or lower.

DonCorleone77 Posted - 1 week ago

$EOLS Evolus discloses publication of Phase 2 study data of 40U Jeuveau The company states: "Evolus announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau(R) (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The "extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau(R) Extra-Strength 40U and two active controls, BOTOX(R) 20U and Jeuveau(R) 20U. Efficacy results demonstrated 26 weeks, or 6 months duration across the multiple metrics presented, including the time it took for patients to return to their baseline GLS score after their treatment, the duration of effect for a patient with at least a one-point GLS improvement, and the time it took a patient to return to their baseline using the Global Aesthetic Improvement Scale. The safety profile was similar across all three arms and overall, 88.9% of adverse events were rated as mild and no serious adverse events were identified."

Stock_Titan Posted - 1 week ago

$EOLS Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau® https://www.stocktitan.net/news/EOLS/evolus-announces-publication-of-safety-and-duration-data-from-phase-9go37du5vlgn.html

junebug67 Posted - 1 week ago

$EOLS

StockInvest_us Posted - 1 week ago

Signal alert: $EOLS - Oversold Trend Short (Undervalued) https://stockinvest.us/l/bJurZ14WFb

Allf Posted - 1 week ago

$EOLS @ $10.X

lknite Posted - 1 week ago

$EOLS if it hits 7.5 again i'll be back

Stock_Titan Posted - 1 week ago

$EOLS Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/EOLS/evolus-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-pwrz77qj6d9y.html

junebug67 Posted - 1 week ago

$EOLS ouch... added

insiderbuyingselling Posted - 03/29/24

$EOLS new insider selling: 6236 shares. http://insiderbuyingselling.com/?t=EOLS

KPOP888 Posted - 03/28/24

$EOLS 전승호 대웅제약 대표는 “대웅제약은 지난해 펙수클루, 엔블로 매출 비중 증가와 나보타 수출확대 등으로 매출, 영업이익, 영업이익률 세 분야에서 역대 최대 실적인 ‘트리플 크라운’을 달성했다

Stock_Titan Posted - 03/26/24

$EOLS Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference https://www.stocktitan.net/news/EOLS/evolus-to-participate-in-the-23rd-annual-needham-virtual-healthcare-j9vr1thpa5c9.html

krayzk4 Posted - 03/25/24

$EOLS @$14.06 I'm going long

kasks83 Posted - 03/25/24

$EOLS boring

RallyRaider Posted - 1 month ago

$EOLS unfolding right now very narrow range recently. breakout soon-- check Tiktok/Instagram and newer celebrities- everybody loves jeuveau and everybody is atleast 10% plastic-- has lost its stigma

knowthyself Posted - 1 month ago

$RVNC I thought this post on X by Jonah Lupton was interesting. "In a recent survey (done by Needham) of users of GLP-1 drugs, 62% of the respondents said they are now more likely to get aesthetic/cosmetic procedures (to help with skin tightening) and/or begin using injectables like Botox and $EOLS Jeuveau as well as fillers to help with overall skin appearance. This is bullish for $INMD and $EOLS (I own both). Also good for $ABBV which owns Allergan which makes Botox. " He didn't mention rvnc, but others on the thread did. As I was saying, once you lose weight, when you look in the mirror, you might say, "hey, why not the face now?" Feeling good, you want to look good. And why not?

insiderbuyingselling Posted - 1 month ago

$EOLS new insider selling: 5672 shares. http://insiderbuyingselling.com/?t=EOLS

insiderbuyingselling Posted - 1 month ago

$EOLS new insider selling: 96566 shares. http://insiderbuyingselling.com/?t=EOLS

kasks83 Posted - 1 month ago

$EOLS why isnit soaring in pre market? any problem?

RonIsWrong Posted - 1 month ago

Survey finds GLP-1 users more inclined to get aesthetic procedures Needham noted that the results reflect sales trends reported by Botox maker Allergan, which has forecasted global 2024 sales growth of 8% year-over-year for cosmetic use of the product. Needham added that neurotoxin makers Evolus $EOLS and Revance Therapeutics $RVNC should also see accelerating growth “as the market returns to its usual high-single digit growth rate.”  Respondents appeared to be particularly keen on longer-acting neurotoxins, with around 47% saying they were interested in the products. Examples of longer-acting neurotoxins are Revance’s Daxxify and Evolus’s Jeuveau, which Needham notes has shown extended duration at higher doses  Based on the survey’s overall results, Needham said that it sees InMode $INMD, in particular, benefitting from current trends. In addition to body contouring products, the company also markets the radiofrequency skin-tightening system Morpheus8 1 of 2

Investor_0007 Posted - 1 month ago

$AMRN I think I will vote against BOD: Louis Sterling (#2) and Patrice Bonfiglio (#3) and see if that might be the way to reduce # of seats on BOD and reduce executive compensation. I hope they are out if they get < 50% of votes and not simply replaced by someone else (another freeloader, $EOLS already has too many of those)...

Investor_0007 Posted - 1 month ago

@chivo12 @pablosplace13 @BuyOnRedSellOnGreen Chivo, I agree with you 100%. $EOLS management should transition from 'dilute anytime we need it' early biotech into revenue-generating multi-product company focused on revenue growth and profit. That would be in line with investors expectation, not perpetually diluting investors that is plaguing early-biotech field.

Investor_0007 Posted - 1 month ago

@pablosplace13 @chivo12 @BuyOnRedSellOnGreen Pablo (and I think also BoraBorak38 at iHub), I am not sure why you consider diluting retail as positive event, especially when happening just a few days after Earnings Call. If $EOLS uses the extra $50M for operations instead of paying off debt (with 15% APR) it is not exactly matching last week's ER call where they stated they are fully funded to break even in Q4. Seems more like $EOLS management wants to pad company's and their own finances (more salaries, bonuses, options, perks) with no regard for retail shareholders.

Investor_0007 Posted - 1 month ago

$EOLS My question below from 2 weeks ago was answered this Monday. Now it is clear that insiders (Leerink Partners and Stifel) temporarily and artifactually jacked up the SP close to $15 to get as high offering price as possible ($14.07). The offering concluded today, so Leerink & Stifel stopped supporting SP as they most likely already sold their options received with this offering and moved on. Most likely SP goes down back to $11 - $13.

kasks83 Posted - 1 month ago

$EOLS what should i do? please let me know the answer!!

BuyOnRedSellOnGreen Posted - 1 month ago

$EOLS this raise will probably be the last the company has to do

DonCorleone77 Posted - 1 month ago

$EOLS Evolus 3.55M share Spot Secondary priced at $14.07 The deal priced at last closing price. Leerink and Stifel are acting as joint book running managers for the offering.